Suppr超能文献

单纯门静脉再通术治疗非肝硬化慢性肝外门静脉阻塞患者的严重门静脉高压症。

Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction.

作者信息

Artru Florent, Vietti-Violi Naik, Sempoux Christine, Vieira Barbosa Joana, Becce Fabio, Sah Nelly, Marot Astrid, Deltenre Pierre, Moschouri Eleni, Fraga Montserrat, Hocquelet Arnaud, Duran Rafael, Moradpour Darius, Rautou Pierre-Emmanuel, Denys Alban

机构信息

Service of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Institute of Liver Studies, King's College Hospital, London, UK.

出版信息

JHEP Rep. 2022 May 25;4(8):100511. doi: 10.1016/j.jhepr.2022.100511. eCollection 2022 Aug.

Abstract

BACKGROUND & AIMS: We aimed to evaluate long-term outcome of patients with chronic non-cirrhotic extrahepatic portal vein obstruction (CNC-EHPVO) who underwent portal vein recanalisation (PVR) without transjugular intrahepatic portosystemic shunt (TIPS) insertion and to determine factors predicting PVR failure and stent occlusion.

METHODS

This retrospective monocentric study included all patients who underwent PVR without TIPS insertion in the context of CNC-EHPVO between the years 2000 and 2019. Primary patency was defined by the absence of a complete stent occlusion on follow-up imaging.

RESULTS

A total of 31 patients underwent PVR with a median follow-up of 52 months (24-82 months). Indications were gastrointestinal bleeding (n = 13), abdominal pain attributed to CNC-EHPVO (n = 7), prior to abdominal surgery (n = 4), and others (n = 7). Technical success was obtained in 27 patients. PVR failure was associated with extension within the intrahepatic portal veins ( = 0.005) and recanalisation for abdominal pain ( = 0.02). Adverse events occurred in 6 patients with no mortality. Anticoagulation was administered in 21 patients after technical success of PVR. In patients with technical success, 5-year primary patency was 73% and was associated with improved muscle mass ( = 0.007) and decreased spleen volume ( = 0.01) at 1 year. Furthermore, 21 (78%) patients with PVR technical success were free of portal hypertension complication at 5 years.

CONCLUSIONS

PVR without TIPS insertion was feasible and safe in selected patients with CNC-EHPVO and portal hypertension with past or expected complications. Primary patency at 5 years was obtained in 3 of 4 patients with technical success of PVR and was associated with a control of complications of CNC-EHPVO. PVR was associated with improvement of sarcopenia and decreased spleen volume at 1 year.

LAY SUMMARY

Patients with chronic obstruction of the portal vein and without cirrhosis or malignancy can develop complications related to the high pressure in the venous system. The present study reports long-term favourable outcome of patients in whom the obstruction was treated with stents.

摘要

背景与目的

我们旨在评估慢性非肝硬化性肝外门静脉阻塞(CNC-EHPVO)患者在未进行经颈静脉肝内门体分流术(TIPS)的情况下接受门静脉再通术(PVR)的长期预后,并确定预测PVR失败和支架闭塞的因素。

方法

这项回顾性单中心研究纳入了2000年至2019年间在CNC-EHPVO背景下接受PVR且未进行TIPS的所有患者。主要通畅性定义为随访成像时无完全支架闭塞。

结果

共有31例患者接受了PVR,中位随访时间为52个月(24-82个月)。适应证包括胃肠道出血(n = 13)、CNC-EHPVO引起的腹痛(n = 7)、腹部手术前(n = 4)以及其他情况(n = 7)。27例患者获得技术成功。PVR失败与肝内门静脉扩展(P = 0.005)和因腹痛进行再通(P = 0.02)相关。6例患者发生不良事件,无死亡病例。PVR技术成功后,21例患者接受了抗凝治疗。在技术成功的患者中,5年主要通畅率为73%,且与1年时肌肉量增加(P = 0.007)和脾体积减小(P = 0.01)相关。此外,21例(78%)PVR技术成功的患者在5年时无门静脉高压并发症。

结论

对于部分患有CNC-EHPVO和门静脉高压且有既往或预期并发症的患者,不进行TIPS的PVR是可行且安全的。PVR技术成功的患者中四分之三在5年时获得主要通畅,且与CNC-EHPVO并发症的控制相关。PVR与1年时肌肉减少症的改善和脾体积减小相关。

简要概述

门静脉慢性阻塞且无肝硬化或恶性肿瘤的患者可能会出现与静脉系统高压相关的并发症。本研究报告了用支架治疗阻塞的患者的长期良好预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dba6/9253474/2fb09d0f0e74/ga1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验